These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 23192682)
1. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. Kim JJ; Yin B; Christudass CS; Terada N; Rajagopalan K; Fabry B; Lee DY; Shiraishi T; Getzenberg RH; Veltri RW; An SS; Mooney SM J Cell Biochem; 2013 Jun; 114(6):1286-93. PubMed ID: 23192682 [TBL] [Abstract][Full Text] [Related]
2. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132 [TBL] [Abstract][Full Text] [Related]
3. Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer. Yin B; Zhang M; Zeng Y; Li Y; Zhang C; Getzenberg RH; Song Y Int J Oncol; 2016 Apr; 48(4):1730-6. PubMed ID: 26892177 [TBL] [Abstract][Full Text] [Related]
4. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1. Li X; Han X; Wei P; Yang J; Sun J Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062 [TBL] [Abstract][Full Text] [Related]
5. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963 [TBL] [Abstract][Full Text] [Related]
6. Skp2 is associated with paclitaxel resistance in prostate cancer cells. Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797 [TBL] [Abstract][Full Text] [Related]
7. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis. Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072 [TBL] [Abstract][Full Text] [Related]
9. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer. Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755 [TBL] [Abstract][Full Text] [Related]
10. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells. Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914 [TBL] [Abstract][Full Text] [Related]
11. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer. Liu Z; Zhu G; Getzenberg RH; Veltri RW J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606 [TBL] [Abstract][Full Text] [Related]
12. Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness. Bizzarro V; Belvedere R; Migliaro V; Romano E; Parente L; Petrella A Cell Adh Migr; 2017 May; 11(3):247-260. PubMed ID: 27834582 [TBL] [Abstract][Full Text] [Related]
13. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer. Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873 [TBL] [Abstract][Full Text] [Related]
14. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Blanchard Z; Paul BT; Craft B; ElShamy WM Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261 [TBL] [Abstract][Full Text] [Related]
15. Resistance to paclitaxel induces glycophenotype changes and mesenchymal-to-epithelial transition activation in the human prostate cancer cell line PC-3. da Fonseca LM; Calvalhan DM; Previato JO; Mendonça Previato L; Freire-de-Lima L Tumour Biol; 2020 Sep; 42(9):1010428320957506. PubMed ID: 32914709 [TBL] [Abstract][Full Text] [Related]
16. In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo. Okugawa K; Kobayashi H; Hirakawa T; Sonoda T; Ogura T; Nakano H J Cancer Res Clin Oncol; 2004 Mar; 130(3):178-86. PubMed ID: 14655049 [TBL] [Abstract][Full Text] [Related]
17. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells. Naito R; Kano H; Shimada T; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Goto M; Nakagawa-Goto K; Mizokami A Prostate; 2021 Apr; 81(5):295-306. PubMed ID: 33493355 [TBL] [Abstract][Full Text] [Related]
18. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Miyake H; Nelson C; Rennie PS; Gleave ME Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138 [TBL] [Abstract][Full Text] [Related]
19. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer. Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513 [TBL] [Abstract][Full Text] [Related]
20. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. Li Y; Mizokami A; Izumi K; Narimoto K; Shima T; Zhang J; Dai J; Keller ET; Namiki M Prostate; 2010 Jan; 70(1):48-60. PubMed ID: 19725034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]